Novo Nordisk settles insulin pricing suit for $100M

[cafead]

via Novo Nordisk, one of the world’s top three manufacturers of insulin, agreed to pay $100 million to settle a 2017 investor suit that alleged the company failed to disclose that it was under the same pricing pressures as its competitors.

article source